# Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes

> **NCT01238224** · PHASE1 · TERMINATED · sponsor: **Vastra Gotaland Region** · enrollment: 22 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tadalafil

## Key facts

- **NCT ID:** NCT01238224
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Durability of study medications could not be guaranteed after the expire date.
- **Last updated:** 2020-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238224, "Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01238224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*